Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

A major breakthrough in cancer genetics has been achieved, paving the way for more effective prevention, early detection, and treatment strategies for patients with BRCA2 mutations.

Medical experts through out di world dey wonder say cancer cases dey increase in younger pipo wey di disease no dey dia ...

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...

A possible link between this mutation and supernumerary nipples was suggested in a 2017 study of a brother and sister. Both siblings had: Breast cancer BRCA2 mutations Two supernumerary nipples The ...

BOISE — A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...